U.S., Nov. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07236645) titled 'Efficacy and Safety of Ginkgo Biloba Extract EGb761(R) in Patients With Diabetic Retinopathy' on Oct. 08.
Brief Summary: This study is a single-center, open-label, parallel-controlled trial, scheduled to commence in October 2025 at the outpatient and inpatient departments of Shanghai General Hospital. Eligible patients with diabetes mellitus and/or non-proliferative diabetic retinopathy (NPDR), who meet the inclusion and exclusion criteria, will be recruited. General and disease-related information will be collected. All eligible participants will be required to voluntarily sign an informed consent form after fully understanding and...